We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals
ELDN

16 hedge funds and large institutions have $27.2M invested in Eledon Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

44% more capital invested

Capital invested by funds: $18.9M → $27.2M (+$8.34M)

0.08% more ownership

Funds ownership: 2.21% → 2.3% (+0.08%)

6% less funds holding

Funds holding: 17 → 16 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$492K
2
Deutsche Bank
Deutsche Bank
Germany
+$232K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$197K
4
AAMU
Amundi Asset Management US
Massachusetts
+$111K
5
PAM
Panagora Asset Management
Massachusetts
+$62K

Top Sellers

Rank Fund Capital Flow
1
LSC
Lyon Street Capital
California
-$319K
2
PPA
Parametric Portfolio Associates
Washington
-$67K
3
UBS Group
UBS Group
Switzerland
-$13K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$5.37K
5
MAM
Meeder Asset Management
Ohio
-$1.24K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$17.8M – – –
BC
2
Boxer Capital
California
$2.27M – – –
RI
3
RTW Investments
New York
$2.11M +$10.3K +100 +0.6%
LSC
4
Lyon Street Capital
California
$1.98M -$319K -3,085 -16%
Renaissance Technologies
5
Renaissance Technologies
New York
$1.37M +$492K +4,762 +78%
Vanguard Group
6
Vanguard Group
Pennsylvania
$547K +$197K +1,902 +78%
Deutsche Bank
7
Deutsche Bank
Germany
$307K +$232K +2,242 +1,138%
DC
8
Derby & Company
Massachusetts
$207K – – –
BlackRock
9
BlackRock
New York
$143K +$26.8K +259 +30%
AAMU
10
Amundi Asset Management US
Massachusetts
$136K +$111K +1,078 New
DS
11
DRW Securities
Illinois
$129K +$17.2K +166 +19%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$98K -$5.37K -52 -6%
PAM
13
Panagora Asset Management
Massachusetts
$76K +$62K +600 New
BRWA
14
B. Riley Wealth Advisors
Florida
$71K +$58K +561 New
Morgan Stanley
15
Morgan Stanley
New York
$16K +$13.2K +128 New
MAM
16
Meeder Asset Management
Ohio
$3.74K -$1.24K -12 -29%
PPA
17
Parametric Portfolio Associates
Washington
– -$67K -743 Closed
UBS Group
18
UBS Group
Switzerland
– -$13K -142 Closed
TRCT
19
Tower Research Capital (TRC)
New York
– -$1K -16 Closed
Bank of America
20
Bank of America
North Carolina
– -$413 -4 Closed
Barclays
21
Barclays
United Kingdom
– -$103 -1 Closed

ELDN Hedge Fund Activity: Q2 2018 in Review

16 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2018, worth a combined $27.2M — up 44% from $18.9M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ELDN and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $492K. The largest seller was Lyon Street Capital, cutting an estimated $319K.

  • 16 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2018, down from 17 in Q1 2018.
  • Funds reported $27.2M of Eledon Pharmaceuticals stock for Q2 2018, up 44% quarter-over-quarter.
  • 4 funds opened new Eledon Pharmaceuticals positions in Q2 2018 and 5 closed out, a net change of -1 holder.
  • The largest Eledon Pharmaceuticals buyer in Q2 2018 was Renaissance Technologies, an estimated $492K added.
  • The largest Eledon Pharmaceuticals seller in Q2 2018 was Lyon Street Capital, an estimated $319K sold.

Based on aggregated 13F filings for Q2 2018.